Literature DB >> 23167384

Molecular characterization of FLT3 mutations in acute leukemia patients in Pakistan.

Mariam Ishfaq1, Arif Malik, Mariam Faiz, Ishfaq Sheikh, Muhammad Asif, Muhammad Nasrullah Khan, Muhammad Saeed Qureshi, Sara Zahid, Abdul Manan, Mahwish Arooj, Mahmood Husain Qazi, Adeel Chaudhary, Mohammed Hussain Alqahtani, Mahmood Rasool.   

Abstract

Fms-like tyrosine kinase 3 (FLT3) performs a vital role in the pathogenesis of hematopoietic malignancies. Therefore in recent times, the focus of several studies was on use of FLT3 as a prognostic marker. The present study investigated the molecular characterization and incidence of FLT3 mutations in acute leukemia patients in Pakistan. A total of 55 patients were studied, of which 25 were suffering from acute lymphoblastic leukemia (ALL) and 30 were suffering from acute myeloid leukemia (AML). The polymerase chain reaction demonstrated FLT3/ ITD mutations in 1 (4%) of 25 ALL patients, a male with the L2 subtype. In AML cases the rate was 4 (13.3%) of 30, three males and one female. The AML-M4 subtype was found in three and the AML M2 subtype in the other. In the AML cases, a statistically significant (p=0.009) relationship was found between WBC (109/L) and FLT3/ ITD positivity. However, no significant relationship was found with other clinical parameters (p>0.05). In acute myeloid leukemia (AML) FLT3/ITD+ mutation was more prevalent in elderly patients 31-40 age groups, 21-30 and 51-60 age groups respectively. In acute lymphoblastic leukemia (ALL) statistically no significant relationship was found between clinical features and FLT3/ITD positivity (p>0.05). However, in acute lymphoblastic leukemia (ALL) FLT3/ITD+ mutation was more commonly found in age groups of 21-30.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23167384     DOI: 10.7314/apjcp.2012.13.9.4581

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  6 in total

1.  The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China.

Authors:  Haimei Gou; Juan Zhou; Yuanxin Ye; Xuejiao Hu; Mengqiao Shang; Jingya Zhang; Zhenzhen Zhao; Wu Peng; Yanhong Zhou; Yi Zhou; Xingbo Song; Xiaojun Lu; Binwu Ying
Journal:  Tumour Biol       Date:  2015-12-16

2.  FLT3 Internal Tandem Duplication and D835 Mutations in Patients with Acute Lymphoblastic Leukemia and its Clinical Significance.

Authors:  Ghaleb Elyamany; Mohammed Awad; Omar Alsuhaibani; Kamal Fadalla; Omer Al Sharif; Mohammad Al Shahrani; Fahad Alabbas; Abdulaziz Al-Abulaaly
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-06-01       Impact factor: 2.576

3.  Frequency of FLT3 Internal Tandem Duplications in Adult Syrian Patients with Acute Myeloid Leukemia and Normal Karyotype.

Authors:  Ismael F Al-Arbeed; Abdulsamad Wafa; Faten Moassass; Bassel Al-Halabi; Walid Al-Achkar; Imad Abou-Khamis
Journal:  Asian Pac J Cancer Prev       Date:  2021-10-01

4.  Detection of TET2 Mutation in Patients with De Novo Acute Myeloid Leukemia: A Mutation Analysis of 51 Iranian Patients.

Authors:  Zahra Chehreghani; Mohammad Hadi Sadeghian; Hossein Ayatollahi; Parisa Bagheri; Zahra Zafari; Omid Rezazadeh; Pourya Arbab Jafari
Journal:  Asian Pac J Cancer Prev       Date:  2022-03-01

Review 5.  Biosensors in clinical practice: focus on oncohematology.

Authors:  Nicola S Fracchiolla; Silvia Artuso; Agostino Cortelezzi
Journal:  Sensors (Basel)       Date:  2013-05-14       Impact factor: 3.576

6.  Frequency and Prognostic Relevance of FLT3 Mutations in Saudi Acute Myeloid Leukemia Patients.

Authors:  Ghaleb Elyamany; Mohammad Awad; Kamal Fadalla; Mohamed Albalawi; Mohammad Al Shahrani; Abdulaziz Al Abdulaaly
Journal:  Adv Hematol       Date:  2014-02-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.